CATX
AMEX · Biotechnology
Perspective Therapeutics Inc
$4.45
-0.15 (-3.26%)
Financial Highlights (FY 2026)
Revenue
2.42M
Net Income
-131,936,619
Gross Margin
23.1%
Profit Margin
-5,452.5%
Rev Growth
-48.8%
D/E Ratio
0.01
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 23.1% | 23.1% | 30.3% | 30.3% |
| Operating Margin | -6,250.8% | -5,625.7% | -17.7% | -15.3% |
| Profit Margin | -5,452.5% | -5,179.9% | -15.6% | -13.0% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 2.42M | 4.73M | 70.28M | 78.45M |
| Gross Profit | 559.7K | 1.09M | 21.26M | 23.73M |
| Operating Income | -151,457,102 | -265,973,447 | -12,462,432 | -12,042,185 |
| Net Income | -131,936,619 | -231,693,574 | -10,926,196 | -10,214,084 |
| Gross Margin | 23.1% | 23.1% | 30.3% | 30.3% |
| Operating Margin | -6,250.8% | -5,625.7% | -17.7% | -15.3% |
| Profit Margin | -5,452.5% | -5,179.9% | -15.6% | -13.0% |
| Rev Growth | -48.8% | -48.8% | +8.8% | +21.6% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 1.63M | 1.63M | 184.55M | 188.23M |
| Total Equity | 280.88M | 280.88M | 242.97M | 259.56M |
| D/E Ratio | 0.01 | 0.01 | 0.76 | 0.73 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -147,407,490 | -273,243,152 | -18,107,687 | -17,982,441 |
| Free Cash Flow | — | — | -6,087,830 | -8,175,378 |